This Week in Cardiology Medscape

More from AHA including SGLT2 inhibitors, blood transfusion after MI; cracks in the armor of Factor XI inhibitors; and renal denervation are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. DAPA MI
Potential Dapagliflozin Benefit Post-MI Is Not a 'Mandate'
https://www.medscape.com/s/viewarticle/998378
- NEJM Evidence: Dapagliflozin After MI https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300286
II. Blood Transfusion Strategy Post MI
In MI With Anemia, Results May Favor Liberal Transfusion: MINT
https://www.medscape.com/viewarticle/998376
- MINT NEJM -- https://www.nejm.org/doi/full/10.1056/NEJMoa2307983
- REALITY https://jamanetwork.com/journals/jama/fullarticle/2776201
- PROTECTED TAVR - https://www.nejm.org/doi/full/10.1056/NEJMoa2204961
III. FACTOR XI
Impressive Bleeding Profile With Factor XI Inhibitor in AF: AZALEA
https://www.medscape.com/viewarticle/998418
Asundexian Phase 3 AF Study Halted for Lack of Efficacy
https://www.medscape.com/viewarticle/998665
- Abelacimab for VTE https://www.nejm.org/doi/full/10.1056/NEJMoa2105872
IV. Renal Denervation
FDA Panel Split on Efficacy of Spyral Renal Denervation
https://www.medscape.com/viewarticle/995800
FDA OKs Symplicity Renal Denervation System for Hypertension
https://www.medscape.com/viewarticle/998664
- SPYRAL HTN OFF MED  -- https://doi.org/10.1016/S0140-6736(20)30554-7
- SPRYAL HTN On Meds (Pilot Lancet 2018 ) https://doi.org/10.1016/S0140-6736(18)30951-6
- SPRYAL HTN ON Meds (Expansion Pilot) https://doi.org/10.1016/j.jacc.2023.08.045
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net

An AHA Recap: SELECT, ORBITA2, and ARTESIA are the trials John Mandrola, MD, reviews in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
American Heart Association 2023 on theHeart.org | Medscape Cardiology
https://www.medscape.com/viewcollection/37277
I. SELECT Trial
Semaglutide 'A New Pathway' to CVD Risk Reduction: SELECT
https://www.medscape.com/viewarticle/998373
Positive Results From SELECT Begins a New Era in Cardiology
https://www.medscape.com/viewarticle/998217
Is It Time for Cardiologists to Treat Obesity?
https://www.medscape.com/viewarticle/998391
- SELECT trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
- SUSTAIN 6 https://www.nejm.org/doi/full/10.1056/nejmoa1607141
II. ORBITA 2
Angioplasty Finally Proven Beneficial in Stable Angina: ORBITA-2
https://www.medscape.com/s/viewarticle/998375
ORBITA-2 Saves Interventional Cardiology and Challenges Current Guidance
https://www.medscape.com/viewarticle/998213
PCI, the Antianginal 'Pill': ORBITA-2 in Detail
https://www.medscape.com/viewarticle/997777
- ORBITA-2; NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2310610
- ORBITA 1 https://doi.org/10.1016/S0140-6736(17)32714-9
III. ARTESIA
Apixaban Cuts Stroke but Ups Bleeding in Subclinical AF: ARTESIA
https://www.medscape.com/viewarticle/998379
Sadly, ARTESIA Doesn't Answer a Common Question in Cardiology
https://www.medscape.com/viewarticle/998215
- NOAH https://www.nejm.org/doi/full/10.1056/NEJMoa2303062
- ARTESIA https://www.nejm.org/doi/10.1056/NEJMoa2310234
- AVERROES https://www.nejm.org/doi/full/10.1056/NEJMoa1007432
- McIntyre Meta-analysis https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067512
- TRENDS https://www.ahajournals.org/doi/10.1161/circep.109.849638
- ASSERT https://doi.org/10.1093/eurheartj/ehx042
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net

Renal denervation, a potential deadly decision in the ED, GLP-1 agonists, and an AHA preview are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Renal Denervation
FDA OKs Paradise Renal Denervation System for Hypertension
https://www.medscape.com/viewarticle/998237
- Company Press Release https://www.recormedical.com/recor-medical-and-otsuka-medical-devices-announce-first-fda-approved-renal-denervation-system-for-the-treatment-of-hypertension/
- Six-month Meta-analysis of RDN Studies https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.123.066941
- March This Week in Cardiology with RDN Discussion https://www.medscape.com/viewarticle/989014
II. Potential Deadly Decisions in the ED
Even One Night in the ED Raises Risk for Death
https://www.medscape.com/viewarticle/998080
- JAMA Internal Medicine Study
III. Tirzepatide Approval
FDA Approves Tirzepatide for Treating Obesity
https://www.medscape.com/viewarticle/998225
- SURMOUNT 2 https://doi.org/10.1016/S0140-6736(23)01200-X
- SURMOUNT 1 https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
IV. AHA Preview
Mandrola's Top Trials to Look for at AHA 2023
https://www.medscape.com/viewarticle/998123
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net

Tricuspid regurgitation therapy, two more left atrial appendage trials, and reflections on being too soft on medical science are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Tricuspid Regurgitation
Trilogy TAVR Safe, Effective in Aortic Regurgitation
https://www.medscape.com/viewarticle/997782
The TRILUMINATE Transcatheter Tricuspid Repair Trial: Positive but No Benefit?
https://www.medscape.com/viewarticle/989105
Transcatheter Tricuspid Valve Repair Effective, Safe for Regurgitation: TRILUMINATE
https://www.medscape.com/s/viewarticle/989103
- TRILUMINATE NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2300525
II. LAA Occlusion
Different Strengths for LAA Closure Devices?
https://www.medscape.com/viewarticle/962893
- Swiss Apero – Original paper https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057859
- Swiss Apero – One-year https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067599
Peri-device Leaks After Watchman https://pubmed.ncbi.nlm.nih.gov/35902169/
TAVR With Left Atrial Appendage Occlusion Non-inferior to TAVR Plus Medical Therapy https://www.medscape.com/viewarticle/997725
- WATCH TAVR Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067312
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net

More on the Million Hearts RCT, ENRICH AF, TAVI vs SAVR, the Partner 3 and Evolut-low-risk trials, and myocardial viability are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Listener Feedback

Million Hearts
CMS 'Million Hearts' CVD Risk Reduction Model Works
https://www.medscape.com/viewarticle/997551
-  RCT JAMA -    https://jamanetwork.com/journals/jama/fullarticle/2810696
AC in ICH - ENRICH AF
Oral Anticoagulation in ICH Patients With AF: New Data https://www.medscape.com/viewarticle/997547
-  Lancet Neurology Meta-analysis https://doi.org/10.1016/S1474-4422(23)00315-0
-  ENRICH AF letter https://doi.org/10.1016/S0140-6736(23)02025-1
II.  TAVI vs SAVR
Low-Risk TAVR Studies: Divergent Long-Term Results 
https://www.medscape.com/viewarticle/997784
-  Partner 3 Main Results
-  Partner 3 – Five Year
-  Original EVOLUT -LR https://www.nejm.org/doi/10.1056/NEJMoa1816885
-  EVOLUT 3-year https://doi.org/10.1016/j.jacc.2023.02.017
-  EVOLUT -LR 4-year https://doi.org/10.1016/j.jacc.2023.09.813
III. Myocardial Viability
Viability-Guided PCI Doubted in Stable Severe CAD: REVIVED-BCIS2
https://www.medscape.com/viewarticle/989101
-  Revived BCIS – Original paper  https://www.nejm.org/doi/10.1056/NEJMoa2206606
-  JAMA Cardiology Viability paper https://jamanetwork.com/journals/jamacardiology/fullarticle/2810727
-  STICH Viability Paper - https://www.nejm.org/doi/full/10.1056/NEJMoa1100358
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net

Listener feedback, oral anticoagulation in patients with ICH, an example of statistical significance but not clinical significance, and statins and diabetes are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Listener Feedback
October 13, 2023 This Week in Cardiology Podcast   https://www.medscape.com/viewarticle/997281
-  European Heart Journal: IVI for PCI   https://doi.org/10.1093/eurheartj/ehad430
-  Elgendy Meta-analysis of Imaging in PCI:   https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.116.003700
-  ULTIMATE:   https://www.jacc.org/doi/10.1016/j.jacc.2018.09.013
-  ILUMEIN IV: https://www.nejm.org/doi/full/10.1056/NEJMoa2305861
-  OCTOBER:  https://www.nejm.org/doi/full/10.1056/NEJMoa2307770
-  Main STEP-HFpEF paper
-  Letter to the Editor on Lack of Obesity Paradox  https://doi.org/10.1016/j.amjcard.2019.04.037
II. Anticoagulation in ICH
Oral Anticoagulation in ICH Patients With AF: New Data   https://www.medscape.com/viewarticle/997547
-   Lancet Neuro   Meta-analysis https://doi.org/10.1016/S1474-4422(23)00315-0
-   ENRICH AF letter   https://doi.org/10.1016/S0140-6736(23)02025-1
III. Million Hearts
CMS 'Million Hearts' CVD Risk Reduction Model Works   https://www.medscape.com/viewarticle/997551
-   RCT JAMA
IV. Statin Choice and Diabetes
April 7, 2023 This Week in Cardiology Podcast
https://www.medscape.com/viewarticle/990542
-   LODESTAR Main Study
-   LODESTAR Substudy
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net